| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2005;112:1644-1650.)
© 2005 American Heart Association, Inc.
Stroke |
From the INSERM U708, Paris, France (C.D., V.B., C.T.); The George Institute for International Health, Sydney, Australia (J.C., S.M., B.N., M.W., C.T.); the UMR6194 CNRS-CEA, and Unite IRM, CHU de Caen, France (O.C., P.G., B.M., N.T.-M.); and the Service de Neurologie, Hôpital Lariboisière, Paris, France (M.-G.B., C.T.).
Correspondence to Dr Christophe Tzourio, INSERM Unit 708, Hôpital La Salpêtrière, 75651 Paris Cedex 13 France. E-mail tzourio{at}chups.jussieu.fr
Received August 18, 2004; revision received March 21, 2005; accepted May 25, 2005.
Background The prevalence of white matter hyperintensities (WMHs) detected on cerebral MRI is associated with hypertension, but it is not known whether blood pressure lowering can arrest their progression. We report here the results of an MRI substudy of PROGRESS (Perindopril Protection Against Recurrent Stroke Study), a randomized trial of blood pressure lowering in subjects with cerebrovascular disease.
Methods and Results The substudy comprised 192 participants who had a cerebral MRI both at baseline and after a mean follow-up time of 36 months (SD=6.0 months). At the first MRI, WMHs were graded with a visual rating scale from A (no WMH) to D (severe WMH). Participants were assigned to a combination of perindopril plus indapamide (or their placebos; 58%) or to single therapy with perindopril (or placebo). At the time of the second MRI, the blood pressure reduction in the active arm compared with the placebo arm was 11.2 mm Hg for systolic blood pressure and 4.3 mm Hg for diastolic blood pressure. Twenty-four subjects (12.5%) developed new WMHs at follow-up. The risk of new WMH was reduced by 43% (95% CI 7% to 89%) in the active treatment group compared with the placebo group (P=0.17). The mean total volume of new WMHs was significantly reduced in the active treatment group (0.4 mm3 [SE=0.8]) compared with the placebo group (2.0 mm3 [SE=0.7]; P=0.012). This difference was greatest for patients with severe WMH at entry, 0.0 mm3 (SE=0) in the active treatment group versus 7.6 mm3 (SE=1.0) in the placebo group (P<0.0001).
Conclusions These results indicate that an active blood pressurelowering regimen stopped or delayed the progression of WMHs in patients with cerebrovascular disease.
Key Words: stroke cerebrovascular disorders magnetic resonance imaging hypertension trials
Related Article:
Circulation 2005 112: 1525-1526.
This article has been cited by other articles:
![]() |
R. P.W. Rouhl, R. J. van Oostenbrugge, J. Damoiseaux, J.-W. C. Tervaert, and J. Lodder Endothelial Progenitor Cell Research in Stroke: A Potential Shift in Pathophysiological and Therapeutical Concepts Stroke, July 1, 2008; 39(7): 2158 - 2165. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Rost, S. M. Greenberg, and J. Rosand The Genetic Architecture of Intracerebral Hemorrhage Stroke, July 1, 2008; 39(7): 2166 - 2173. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. M. Hajjar, M. Keown, P. Lewis, and A. Almor Angiotensin Converting Enzyme Inhibitors and Cognitive and Functional Decline in Patients with Alzheimer's Disease: An Observational Study American Journal of Alzheimer's Disease and Other Dementias, March 1, 2008; 23(1): 77 - 83. [Abstract] [PDF] |
||||
![]() |
E. E. Smith, S. Egorova, D. Blacker, R. J. Killiany, A. Muzikansky, B. C. Dickerson, R. E. Tanzi, M. S. Albert, S. M. Greenberg, and C. R. G. Guttmann Magnetic Resonance Imaging White Matter Hyperintensities and Brain Volume in the Prediction of Mild Cognitive Impairment and Dementia Arch Neurol, January 1, 2008; 65(1): 94 - 100. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. O'Sullivan Leukoaraiosis Practical Neurology, January 1, 2008; 8(1): 26 - 38. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. O'Rourke Arterial aging: pathophysiological principles Vascular Medicine, November 1, 2007; 12(4): 329 - 341. [Abstract] [PDF] |
||||
![]() |
B. Minguez, A. Rovira, J. Alonso, and J. Cordoba Decrease in the Volume of White Matter Lesions with Improvement of Hepatic Encephalopathy AJNR Am. J. Neuroradiol., September 1, 2007; 28(8): 1499 - 1500. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schmidt, K. Petrovic, S. Ropele, C. Enzinger, and F. Fazekas Progression of Leukoaraiosis and Cognition Stroke, September 1, 2007; 38(9): 2619 - 2625. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. F. O'Rourke and J. Hashimoto Mechanical Factors in Arterial Aging: A Clinical Perspective J. Am. Coll. Cardiol., July 3, 2007; 50(1): 1 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF] |
||||
![]() |
W. B. White The Riskiest Time for the Brain: Could the Nighttime Be the Right Time for Intervention? Hypertension, June 1, 2007; 49(6): 1215 - 1216. [Full Text] [PDF] |
||||
![]() |
C. Opherk, N. Peters, M. Holtmannspotter, A. Gschwendtner, B. Muller-Myhsok, and M. Dichgans Heritability of MRI Lesion Volume in CADASIL: Evidence for Genetic Modifiers Stroke, November 1, 2006; 37(11): 2684 - 2689. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Viswanathan, J.-P. Guichard, A. Gschwendtner, F. Buffon, R. Cumurcuic, C. Boutron, E. Vicaut, M. Holtmannspotter, C. Pachai, M.-G. Bousser, et al. Blood pressure and haemoglobin A1c are associated with microhaemorrhage in CADASIL: a two-centre cohort study Brain, September 1, 2006; 129(9): 2375 - 2383. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Greenberg Small Vessels, Big Problems N. Engl. J. Med., April 6, 2006; 354(14): 1451 - 1453. [Full Text] [PDF] |
||||
![]() |
A. Viswanathan and H. Chabriat Cerebral Microhemorrhage Stroke, February 1, 2006; 37(2): 550 - 555. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Schiffrin Blood Pressure Lowering in PROGRESS (Perindopril Protection Against Recurrent Stroke Study) and White Matter Hyperintensities: Should This Progress Matter to Patients? Circulation, September 13, 2005; 112(11): 1525 - 1526. [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |